In a phase 2a trial in myasthenia gravis, Cytokinetics’ drug tirasemtiv showed dose-related beneficial effects and no serious adverse events
posted on December 12, 2012 - 9:10am
The experimental drug tirasemtiv has shown promise in a phase 2a clinical trial in 32 people with myasthenia gravis (MG). Improvements in general and respiratory muscle function occurred in response to the medication.
Six hours after receiving a single, oral dose of tirasemtiv, study participants showed improvements on a standardized scale of MG severity (the Quantitative MG score) and in forced...